Deep Dive · rNPV Rank 18Grant / non-commercial

Enhancement of Adenoviral Oncolytic Activity by Modification of the E1A Gene Product

Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.

Indication

prostate cancer

Modality

Gene Therapy

Mechanism

oncolytic adenovirus (E1A modification)

Target

androgen receptor

rNPV Envelope

Low

-$36.6M

costs +25% · peak −25%

Base

-$29.1M

cumulative PoS 0.6%

High

-$21.7M

costs −25% · peak +25%

This is an illustrative oncolytic adenovirus envelope for cohort consistency only. The patent is expired and the asset is an old E1A/AR prostate-selective method, so PoS is reduced versus active clinical adenoviral programs.

01

Composite score breakdown

Locked rubric — 40/30/30 weights

Clinical relevance · 40%

0.50

Modality fit · 30%

0.74

Whitespace · 30%

0.50

Composite 0.572 — composite-score rank #40 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#18) to match the index ordering.

02

Comparators

Real programs anchoring the engine inputs

E1A/androgen-receptor chimeric prostate-selective adenovirus

The direct asset: a target-cell-specific replication-competent adenovirus using prostate-specific transcriptional control and modified E1A/AR biology for selective cytotoxicity.

Indication: Prostate cancer
Modality: Oncolytic adenovirus
Approval:
Peak revenue:

Criteria 1 and 2: exact modality and indication; old platform with expired patent.

CAN-2409 / ProstAtak

Adjacent prostate adenoviral clinical archetype. It is not E1A-modified CRAd, but it anchors contemporary prostate adenoviral development.

Indication: Localized prostate cancer
Modality: Adenoviral gene therapy / immunotherapy
Approval:
Peak revenue:

Criteria 2 and 4: same organ and viral platform family, different vector design.

Oncorine / H101

Approved oncolytic adenovirus precedent; useful as a regulatory archetype but far from prostate-selective E1A/AR design.

Indication: Nasopharyngeal/head and neck cancer with chemotherapy in China
Modality: Oncolytic adenovirus
Approval: 2005
Peak revenue:

Criteria 3 and 4: approved oncolytic adenovirus archetype only.

03

Stage profile

Asset-specific cost, duration, and PoS by stage

StageCostDurationPoSCitations
Preclinical$14.0M24 mo26.0%[0]
Phase I$50.0M18 mo50.0%[0] [1]
Phase II$110.0M30 mo18.0%[1] [2]
Phase III$230.0M42 mo34.0%[1] [2]
NDA/BLA Review$15.0M12 mo80.0%[2]

Multiplier handling: No multipliers eligible for this asset under the locked methodology. See methodology for the rule.

04

Peak revenue and discount rate

$75.0M peak · WACC 16.0%

Peak revenue. With expired IP and no active product, only a low illustrative value is defensible. The $75M figure reflects possible historical/academic platform value, not a proprietary prostate adenovirus revenue forecast.

WACC. Expired, old, preclinical oncolytic adenovirus IP has very high commercial and translational risk.

05

Sensitivity (tornado)

Top drivers of rNPV variance

Cost: Preclinical
$10M$18M
-$25.5M
-$32.8M
$7.2M
PoS: Preclinical
21%31%
-$25.7M
-$32.5M
$6.8M
Cost: Phase I
$35M$65M
-$26.5M
-$31.7M
$5.2M
Cost: Phase II
$77M$143M
-$27.0M
-$31.3M
$4.2M
WACC
13%19%
-$31.2M
-$27.3M
+$4.0M
PoS: Phase I
40%60%
-$27.4M
-$30.8M
$3.4M

Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$29.1M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.

06

Monte Carlo distribution

1,000 trials · rpNPV mode

Failure cluster · 100.0% of paths
$0 ↓
Success tail · 0.0% of paths
P50 medianBase rNPV (mean)-$256.2MeNPV outcome bin (sqrt-scaled height)-$1.2M

This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).

P5

-$114.9M

P25

-$30.1M

P50 (median)

-$12.6M

P75

-$7.7M

P95

-$4.6M

Prob ≥ 0

0.0%

07

Evidence register

3 per-assumption citations

AssumptionSourceDateConfidence
JHU asset is E1A-modified prostate-selective oncolytic adenovirus with expired patent
cmo_findings.asset_class_reality
Enhancement of Adenoviral Oncolytic Activity by Modification of the E1A Gene Product
regulatory
2014-10-07high
Prostate adenoviral clinical archetype
comparators[1]
Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
trial_disclosure
2025-01-01high
Approved oncolytic adenovirus archetype
comparators[2]
Oncorine, the World First Oncolytic Virus Medicine and its Update in China
peer_review
2017-11-01high
08

Thesis

Why this asset earns its rank

This is an old oncolytic adenovirus method, not a fundable gene-therapy product. The JHU technology modifies the E1A gene product in a prostate-selective replication-competent adenovirus, using androgen-receptor/prostate-specific transcriptional control to drive cytotoxicity. The listed patent is expired. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified grant_non_commercial.

The comparator set is purely archetypal. CAN-2409 shows that prostate adenoviral immunotherapy can still be clinically relevant, while Oncorine shows narrow adenoviral approval precedent, but neither revives an expired E1A/AR prostate CRAd patent. The engine result is -$36.6M to -$21.7M, with a base rNPV of -$29.1M and cumulative PoS of 0.6%; that low placeholder is appropriate for old, expired, non-active IP.

Verdict: scientifically coherent but commercially exhausted. It earns its rank from prostate relevance and the gene_therapy bucket, while a CMO would immediately flag expired patent status, old-vector design, and the absence of a current development sponsor.

09

Key risks

Asset-specific, not generic biotech risks

  • Expired IP: the US patent listed by JHU expired in 2023, limiting any standalone licensing value.
  • Modality mismatch: this is an oncolytic adenovirus design, not conventional gene therapy.
  • Clinical relevance gap: no active E1A/AR prostate CRAd product is identified from the asset file.
  • Modern competition: prostate cancer standards have evolved substantially since the 2002 invention date.